Therapeutic strategies are needed to protect dopaminergic neurons in Parkinson’s disease (PD) patients. Oxidative stress caused by dopamine may play an important role in PD pathogenesis. Selective autophagy of mitochondria (mitophagy), mainly regulated by PINK1 and PARKIN, plays an important role in the maintenance of cell homeostasis. Mutations in those genes cause accumulation of damaged mitochondria, leading to nigral degeneration and early-onset PD. AMBRA1^{ActA} is a fusion protein specifically expressed at the mitochondria, and whose expression has been shown to induce a powerful mitophagy in mammalian cells. Most importantly, the pro-autophagy factor AMBRA1 is sufficient to restore mitophagy in fibroblasts of PD patients carrying PINK1 and PARKIN mutations. In this study, we investigated the potential neuroprotective effect of AMBRA1-induced mitophagy against 6-hydroxydopamine (6-OHDA)- and rotenone-induced cell death in human neuroblastoma SH-SY5Y cells. We demonstrated that AMBRA1^{ActA} overexpression was sufficient to induce mitochondrial clearance in SH-SY5Y cells. We found that apoptosis induced by 6-OHDA and rotenone was reversed by AMBRA1-induced mitophagy. Finally, transfection of SH-SY5Y cells with a vector encoding AMBRA1^{ActA} significantly reduced 6-OHDA and rotenone-induced generation of reactive oxygen species (ROS). Altogether, our results indicate that AMBRA1^{ActA} is able to induce mitophagy in SH-SY5Y cells in order to suppress oxidative stress and apoptosis induced by both 6-OHDA and rotenone. These results strongly suggest that AMBRA1 may have promising neuroprotective properties with an important role in limiting ROS-induced dopaminergic cell death, and the utmost potential to prevent PD or other neurodegenerative diseases associated with mitochondrial oxidative stress.

Keywords: cell death, oxidative stress, in vitro models, Parkinson’s disease, mitophagy
INTRODUCTION

Parkinson’s disease (PD) is a chronic and severe neurodegenerative disorder characterized by a progressive and selective death of dopaminergic neurons in the substantia nigra. The cellular loss (among 50%–70%) in the ventral area of the substantia nigra pars compacta is the main pathological hallmark of PD. Although Parkinsonism is usually a sporadic disease, there is also a familial component related to a growing number of single gene mutations. Among these, mutations in mitochondrial genes encoding PINK1, PARKIN and DJ-1 proteins promote autosomal recessive PD. Although the exact causes defining PD are largely unknown, mitochondrial oxidative stress and accumulated dysfunctional mitochondria are critical factors in the disease onset. The clearance of dysfunctional mitochondria can be regulated by a selective form of autophagy, known as mitophagy (Lemasters, 2005). Mitophagy is a self-degradative process that allows the elimination of ubiquitin-targeted mitochondria through lysosomal digestion. Both PINK1 and PARKIN are key factors in mitophagy induction: PINK1 is a Ser-Thr kinase that mediates the phospho-ubiquitin signal, thus recruiting the E3 ubiquitin ligase PARKIN at the mitochondria. Once at the mitochondria, PARKIN amplifies the ubiquitin signal on the mitochondrial surface, this leading to their recruitment into the autophagosome (Lazarou et al., 2015). We have previously demonstrated that a mitophagy-targeted fusion protein, AMBRA1ActA, is a novel powerful inducer of mitophagy in mammalian cells (Strappazzon et al., 2015). Most importantly, we demonstrated that AMBRA1 restores mitophagy in mouse embryonic fibroblasts from PINK1−/− mice, but also in fibroblasts from PD patients, in which PINK1 and PARKIN were mutated; altogether, these findings highlighted AMBRA1 as an alternative mediator of mitophagy to maintain mitochondrial homeostasis in PINK1-PARKIN-related PD (Strappazzon et al., 2015). In the PD context, oxidative stress is widely considered to be a key factor in both familial and sporadic forms of the disease (Sanders et al., 2014). It results from an imbalance of pro-oxidants/anti-oxidants homeostasis that leads to an abnormal production of reactive oxygen species (ROS), whose overproduction generates damage of both neurons and astrocytes (Lin and Beal, 2006).

In this study, we investigated the effect of AMBRA1ActA protein in two oxidative stress models, evoked by disruption of the mitochondrial activity induced by: (1) blockade of mitochondrial complexes I and IV by using the pro-oxidant derivate of dopamine, 6-hydroxydopamine (6-OHDA; Glinka et al., 1997); or (2) blockade of mitochondrial complex I by using rotenone, a pesticide that has been associated with increased risk of familial and sporadic forms of PD (Li et al., 2003; Chin-Chan et al., 2015). The blockade of mitochondrial complexes I and IV generates damage of both neurons and astrocytes (Lin and Beal, 2006).

Materials and Methods

Cell Culture

Human neuroblastoma SH-SY5Y cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, GIBCO) supplemented with 10% FBS (GIBCO), at 37°C in a humidified atmosphere of 5% CO2.

Reagents

3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) was purchased from Promega. 6-hydroxydopamine (6-OHDA), rotenone, the lysosome inhibitor NH4Cl and the Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) were purchased from Sigma Aldrich.

Transient Transfection and Plasmids

Human neuroblastoma SH-SY5Y cells were transfected using TransIT-X2® Dynamic Delivery System (MIR 6003, Mirus) according to the standard protocol. The Myc-AMBRA1ActA plasmid was cloned as described in Strappazzon et al. (2015). The Mito-DsRED construct encodes for human Cox8A mitochondria signal peptide which is fused with wild-type-DsRED in PcDNA3 vector (Invitrogen). The Mito-DsRED-AMBRA1ActA is a bidirectional vector encoding for both Mito-DsRED and AMBRA1ActA. For small interfering RNA (siRNA)-mediated knockdown of AMBRA1, siRNA against AMBRA1 or siRNA-Ctr (Invitrogen, were transiently transfected using Lipofectamine 2000, according to the manufacturer’s protocol. ShRNA PARKIN or shRNA Control were transfected in SH-SY5Y cells using Turbofect Transfection reagent (Thermo Fisher Scientific, R0531), according to the standard instructions.

Antibodies

We use the following antibodies: anti-Myc (Santa Cruz Biotechnology, 9E10), anti-ACTIN (Sigma-Aldrich, A2228), anti-PARP (Cell Signaling, 9542), anti-MnSOD (Enzo Life Sciences, 110F), anti-TOM20 (Santa Cruz Biotechnology, sc-FL145) and anti-HSP60 (Santa Cruz Biotechnology, sc-13966).
**Immunofluorescence Analysis**

SH-SY5Y cells were fixed in 4% of paraformaldehyde and permeabilized with 0.4% Triton X-100. Fixed cells were blocked in 2% normal goat serum (Sigma-Aldrich, G9023) in PBS and incubated with primary antibody over night. Cells were then washed with PBS 3 × 5 min and incubated with secondary antibody for 1 h. After 3 × 5 min of PBS washing, coverslips were mounted on glass slides and finally analyzed by confocal microscopy analysis under Zeiss LSM 700 100× oil-immersion objective (CLSM700; Jena, Germany), Zoe Fluorescence cell imager (Biorad, 1450031) or Ultraview Vox (Perkin Elmer).

**Confocal Image Analysis**

The TOM20 and HSP60 intensities and the area occupied by the signal per cell, in conditions indicated in the text, were calculated through the NIH ImageJ software in 10 different fields of three independent experiments. Colocalization measurements were made through the JACOP plugin (Bolte and Cordelières, 2006) of the NIH ImageJ software. M1 manders colocalization coefficients (MCC) of mitochondria overlapping LC3, p62 and Ubiquitin were calculated on single cells in 10 different fields of three independent experiments upon overexpression of either Mito-DsRED or Mito-DsRED-AMBRA1ActA to highlight wild type mitochondria and mitoaggresomes, respectively. Thresholds were not set by the operator, but automatically calculated by the software to avoid biased data. All microscope quantifications shown in the article were performed by a blind approach.

**Determination of Cell Viability**

Cell vitality was estimated by the MTS assay or by counting the number of condensed or fragmented nuclei (DAPI staining). For the MTS assay, the cytotoxicity of 6-OHDA or rotenone on SH-SY5Y cells was determined using the CellTiter96 Aqueous One Solution Assay (Promega, Madison, WI, USA). Indeed, SH-SY5Y cells was transfected using TransIT-X2® Dynamic Delivery System (MIR 6003, Mirus). Six hours after transfection, cells were split into 96-well dishes and treated with 6-OHDA (100 µM) or rotenone (10 µM). After 18 h, the CellTiter 96 AQueous One Solution Reagent was added to each well. The plate was then read at 490 nm in a Victor3 plate reader at 37°C (PerkinElmer Life and Analytical Sciences, Shelton, CT, USA). For pyknotic nuclei counting, Mito-DsRED or Mito-DsRED-AMBRA1ActA transfected cells were fixed in 4% paraformaldehyde (Merck Millipore, 104005) in PBS (GIBCO, BE17-512F) for 10 min at 37°C and stained with DAPI (Sigma Aldrich, D9542) in PBS for 15 min at room temperature. Cells were washed three times with PBS, then mounted and observed under Zoe microscope. For each condition, random images were captured and cell viability was then scored on the basis of nuclear morphology; cells containing condensed or fragmented nuclei were counted as dying or dead cells. All microscope quantifications shown in the article were performed by a blind approach.

**Protein Oxidation Assay**

SH-SY5Y cells were transfected and treated with 6-OHDA or rotenone, as described above. The DPN-derivatized proteins containing carbonyl groups were evaluated by using the OxyBlot Protein Oxidation Detection Kit (Millipore S7150), according to the standard protocol.

**Measure of Δψm and Superoxide Production**

Cells were transfected with the bicistronic vector Tweep-GFP-AMBRA1ActA or Tweep-GFP alone and subsequently treated or not with 100 µM 6-OHDA and 10 µM rotenone 6 h post transfection. After 18 h of treatment, cells were incubated with 5 nM Tetratetethylrhodamine methyl ester (TMRM, Molecular Probes) in 10% FBS+DMEM for 30 min at 37°C or with 5 µM MitoSOX Red reagent (Molecular Probes) in 10% FBS+DMEM for 10 min at 37°C in a 5% CO2 incubator. Finally, cells were analyzed through the flow cytometer BD Accuri C6. TMRM and MitoSOX Red fluorescence intensities were measured in GFP positive cells and read in the FL3 channel upon stimulation at 488 nm.

**High Levels of Mitochondria-Targeted AMBRA1 (AMBRA1ActA) in Human Neuroblastoma SH-SY5Y Cells Induce Perinuclear Distribution of Mitochondria, Accompanied by Mitochondria Clearance**

In this case, we wanted to check for the localization of the AMBRA1ActA protein and for a putative mitochondrial clearance in SH-SY5Y cells. To this end, we performed a confocal microscopy analysis in SH-SY5Y cells transfected with a vector encoding PcDNA3 as a control or Myc-AMBRA1ActA. We then fixed cells and stained their mitochondria network using an antibody directed against TOM20. We found that AMBRA1ActA surrounds aggregated mitochondria. Most importantly, we observed that AMBRA1ActA overexpression induces per se a strong relocalization of the mitochondrial network around the perinuclear envelope, thus leading to the formation of structures similar to those previously described as “mito-aggresomes” (Lee et al., 2010; Figure 1A). The reduction of both the area of mitochondria and the TOM20 signal intensity in AMBRA1ActA-transfected cells confirmed that AMBRA1ActA stimulates massive mitophagy also in SH-SY5Y cells. Moreover, in order to ascertain that mito-aggresome structures were
specific for AMBRA1 mitochondrial localization coupled with a reduction of mitochondrial marker levels, we performed a confocal microscope analysis, in which SH-SY5Y cells were transfected with PcDNA3, Myc-AMBRA1<sup>ActA</sup>, Venus<sup>ActA</sup>, a plasmid encoding the ActA sequence fused with the fluorescent reporter protein Venus (Nagai et al., 2002), and with the wild-type form of AMBRA1 lacking the ActA sequence. Further, the AMBRA1<sup>ActA-LIRAA</sup> plasmid, encoding an AMBRA1<sup>ActA</sup> isoform mutated in its LIR motif and less active in mitophagy (due to a reduction of LC3B binding), was used to complete this
analysis (Strappazzon et al., 2015; Supplementary Figure S1). We next analyzed whether AMBRA1<sup>A<sub>CTA</sub></sup> expression was able to induce mitophagy, as we already described in HEK293, HeLa and MEF cells (Strappazzon et al., 2015). To this end, SH-SY5Y cells were transfected with a bicistronic vector coding for Mito-DsRED alone (red staining of mitochondria) or encoding both Mito-DsRED and AMBRA1<sup>A<sub>CTA</sub></sup> (Mito-DsRED-AMBRA1<sup>A<sub>CTA</sub></sup>) for 24 h; first, we analyzed mitophagy induction by looking to well-known markers of autophagosome formation, such as LC3 and p62 (Kabeya et al., 2000; Pankiv et al., 2007). Indeed, we observed an increase in the accumulation of LC3 dots, but not p62, in Mito-DsRED-AMBRA1<sup>A<sub>CTA</sub></sup>-positive mitochondria, suggesting that AMBRA1<sup>A<sub>CTA</sub></sup> promotes an LC3-dependent, but p62-independent mitophagy in SHSY5Y cells (Figure 1B). In addition, we checked for ubiquitin staining and found that mito-aggresomes are positive for Ubiquitin (Figure 1C). These data proved that AMBRA1<sup>A<sub>CTA</sub></sup> induces mito-aggresomes positive for LC3 and Ubiquitin, but negative for p62 also in SHSY5Y cells. We next confirmed that AMBRA1<sup>A<sub>CTA</sub></sup> was able to induce mitophagy in these cells, by using a biochemical approach. Indeed, we checked the level of MnSOD, a mitochondrial protein, following AMBRA1<sup>A<sub>CTA</sub></sup> transfection in SH-SY5Y cells in the presence or absence of a lysosomal inhibitor, ammonium chloride (NH<sub>4</sub>Cl), known to prevent the autophagy flux by inhibiting the fusion of autophagosomes with lysosomes (Hart and Young, 1991). As expected, AMBRA1<sup>A<sub>CTA</sub></sup> was able to induce a strong reduction of MnSOD protein levels. In addition, the NH<sub>4</sub>Cl treatment resulted in a significantly higher level of mitochondrial protein accumulation in AMBRA1<sup>A<sub>CTA</sub></sup>-positive cells, hence indicating that autophagosome formation induced by AMBRA1<sup>A<sub>CTA</sub></sup> overexpression is responsible for MnSOD degradation by the lysosome (Figure 1D). The ability of AMBRA1<sup>A<sub>CTA</sub></sup> to mediate mitophagy in these cells was confirmed also by looking at another mitochondrial marker, COXIV (data not shown). Finally, we checked in SH-SY5Y cells downregulated for PARKIN expression whether AMBRA1<sup>A<sub>CTA</sub></sup> was able to induce mitophagy. As shown in Figure 1E, AMBRA1<sup>A<sub>CTA</sub></sup> induces mitophagy also in PARKIN-deficient SH-SY5Y cells. Altogether, these observations demonstrate that AMBRA1<sup>A<sub>CTA</sub></sup> transfection triggers per se a fully functional and massive mitophagy in SH-SY5Y cells, which is independent of both PINK1/PARKIN and p62, but dependent of LC3 and Ubiquitin.

**AMBRA1<sup>A<sub>CTA</sub></sup>-Induced Mitophagy Protects SH-SY5Y Cells From Neurotoxicity Induced by 6-OHDA**

We have previously demonstrated that AMBRA1-induced mitophagy is able to trigger mitophagy in fibroblasts from PD patients bearing PINK1 or PARKIN mutations, this highlighting the fact that AMBRA1 can serve as an alternative mediator of mitophagy to maintain mitochondrial turnover in PINK1/PARKIN-related PD. Thus, since mitophagy plays an important role in the quality control of mitochondria and in the maintenance of cell homeostasis, we hypothesized that AMBRA1<sup>A<sub>CTA</sub></sup>-induced mitophagy could be protective in well-known in vitro models of PD. We thus decided to test the potential effect of AMBRA1<sup>A<sub>CTA</sub></sup> in SH-SY5Y cells treated with 6-OHDA (100 µM, 18 h). In this context, neurotoxicity is induced by blocking activities of mitochondria complexes I and IV (Glinka et al., 1997). In an MTS assay (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) we observed, as expected, a reduction in the metabolic activity of PcDNA3-positive cells following 6-OHDA, when compared to PcDNA3-positive control cells, treated only with the vehicle. By contrast, MTS metabolism was improved in AMBRA1<sup>A<sub>CTA</sub></sup>-positive cells (Figure 2A). These findings suggest that AMBRA1<sup>A<sub>CTA</sub></sup>-positive cells are more resistant to neurotoxicity induced by 6-OHDA. To confirm this result, SH-SY5Y cells were transfected with Venus<sup>A<sub>CTA</sub></sup> or Mysc-AMBRA1<sup>A<sub>CTA</sub></sup> or Mysc-AMBRA1<sup>A<sub>CTA</sub>LIRAA</sub> for 24 h; cell viability was then measured by means of DAPI nuclear staining, following 6-OHDA treatment. After 6-OHDA treatment, about 80% of Venus<sup>A<sub>CTA</sub></sup> or 64% of Mysc-AMBRA1<sup>A<sub>CTA</sub>LIRAA</sub> positive cells exhibited condensed or fragmented nuclei, while only 40% of Mysc-AMBRA1<sup>A<sub>CTA</sub></sup>-positive cells showed these apoptotic features (Figure 2B). Therefore, high levels of AMBRA1 at the mitochondria improve the survival of SH-SY5Y cells following 6-OHDA treatment.

To strengthen our finding we next checked, by western-blot analysis, the occurrence of poly (ADP-ribose) polymerase-1 (PARP-1) cleavage, a well-known substrate of caspase-3, in cells over-expressing PcDNA3 or Mysc-AMBRA1<sup>A<sub>CTA</sub></sup> upon 6-OHDA treatment. As shown in Figure 2C, the cleavage of PARP-1 is reduced in cells overexpressing Mysc-AMBRA1<sup>A<sub>CTA</sub></sup> compared to cells expressing the control vector (Figure 2C). These results strongly support the existence of a protective effect of AMBRA1<sup>A<sub>CTA</sub></sup> against neurotoxicity induced by 6-OHDA in a human neuroblastoma cell line. Since Van Humbeeck et al. (2011) demonstrated that downregulation of AMBRA1 inhibits mitophagy in SH-SY5Y cells, we decided to check whether down-regulation of AMBRA1 expression by RNA interference (siRNA) could lead to a stronger apoptosis in 6-OHDA-treated cells. As shown in Figure 2D, downregulation of AMBRA1 increases apoptosis, as indicated by increased PARP cleavage, when compared to SiRNA-Ctr positive cells. Moreover, the level of the mitochondrial marker MnSOD does not decrease in a toxic context affecting mitochondria in the absence of AMBRA1 (Supplementary Figure S2A). These results suggest that AMBRA1 plays pro-survival functions in SH-SY5Y cells following 6-OHDA treatment.

These results indicate that AMBRA1<sup>A<sub>CTA</sub></sup> confers protection from cell death-induced by 6-OHDA thanks to its mitophagic activity.

**AMBRA1<sup>A<sub>CTA</sub></sup>-Induced Mitophagy Protects SH-SY5Y Cells From Neurotoxicity Induced by Rotenone**

To ascertain that AMBRA1<sup>A<sub>CTA</sub></sup> expression was also protective in another ROS-induced dopaminergic cell death model system,
we decided to test the effect of AMBRA1<sup>ActA</sup> in SH-SY5Y cells treated with another “well-known” dopaminergic neurotoxin, rotenone. In this context, neurotoxicity is induced by blocking activity of mitochondria complex I (Glinka et al., 1997). In analogy with 6-OHDA treatment, by using the MTS assay, we observed a reduction in metabolic activity of PcDNA3-positive cells following rotenone, when compared with PcDNA3-positive controls cells treated only with the vehicle. By contrast, MTS metabolism was slightly improved in AMBRA1<sup>ActA</sup>-positive cells (Figure 3A). These findings confirm that AMBRA1<sup>ActA</sup>-positive cells are in general more resistant to neurotoxicity induced by different agents, in this case rotenone. In order to corroborate our results, we transfected SH-SY5Y cells with Venus<sup>ActA</sup> or Myc-AMBRA1<sup>ActA</sup> or Myc-AMBRA1<sup>ActA</sup>LIRAA plasmids for 24 h; cell viability was then evaluated by using DAPI nuclear staining upon rotenone treatment. As shown in
**Figure 3** | AMBRA1<sup>ActA</sup> improves vitality of SH-SYSY cells treated with rotenone. (A) SH-SYSY cells were transfected with vectors coding for PcDNA3 or for Myc-AMBRA1<sup>ActA</sup> and then treated with rotenone (10 µM). Viable cells were estimated using the MTS assay. Results are expressed as arbitrary unit (A.U.). Each point represents the mean (± SD) of triplicate wells from three independent experiments. Statistical analysis was performed using One-way ANOVA. *P < 0.05. **P < 0.01. (B) SH-SYSY cells were transfected with vectors encoding Venus-ActA or Myc-AMBRA1<sup>ActA</sup> or Myc-AMBRA1<sup>ActA</sup>LIRAA for 24 h. Six hours after transfection, cells were treated with rotenone (10 µM). After DAPI staining, cells with condensed or fragmented nuclei were scored as pyknotic (arrows indicate pyknotic nuclei). The graph shows the percentage of pyknotic nuclei in transfected cells (± S.D). For each condition, transfected cells were counted in random fields from three independent experiments. Statistical analysis was performed using One-way ANOVA. ***P < 0.0001; **P < 0.001; *P < 0.05. (C) SH-SYSY cells were transfected with vectors encoding PcDNA3 or Myc-AMBRA1<sup>ActA</sup> for 24 h. Six hours after transfection, cells were treated with rotenone (10 µM). After extraction of proteins, we performed a western blot analysis using antibodies directed against AMBRA1 (Myc), PARP/Cleaved-PARP and ACTIN. The graph shows the cleaved PARP/full-length PARP ratio, resulting as the mean of three independent experiments (± S.D). n = 3. One-way ANOVA. *P < 0.05. (D) SH-SYSY cells transfected with a siRNA-Ctr or siRNA-AMBRA1 were treated with 6-OHDA for 18 h. Total lysates were subjected to immunoblotting for AMBRA1, PARP and ACTIN antibodies. The graph represents the cleaved PARP/Final-length PARP ratio (± S.D). Statistical analysis was performed using One-way ANOVA. *P < 0.05. n = 3 independent experiments.

**Figure 3B**, AMBRA1<sup>ActA</sup> expression is sufficient to robustly reduce the number of pyknotic nuclei in transfected individual cells. Therefore, high levels of AMBRA1 at the mitochondria with a marked mitophagy activity (AMBRA1<sup>ActA</sup>) greatly improve...
survival of SH-SY5Y cells, following both 6-OHDA and rotenone treatments.

Again, by western blot analysis upon rotenone treatment, we observed an inhibition of PARP-1 cleavage in cells over-expressing Myc-AMBRA1\textsuperscript{ActA} compared to PcDNA3-positive cells (Figure 3C). Altogether, these results strongly support a protective role for AMBRA1\textsuperscript{ActA} in the classical toxic in vitro model of PD induced by rotenone. We also checked in this context whether down-regulation of AMBRA1 expression using siRNA was able to trigger a stronger apoptosis following rotenone treatment. As shown in Figure 3D, downregulation of AMBRA1 increases apoptosis, as indicated by increased PARP cleavage. These results suggest that, also upon rotenone treatment of SH-SY5Y cells, endogenous AMBRA1 is involved in a pro-survival pathway. Moreover, SH-SY5Y cells in which AMBRA1 was downregulated through siRNA, were treated with rotenone in order to analyze the level of the mitochondrial marker MnSOD. In line with the 6-OHDA treatment, we observed no decrease in a toxic context affecting mitochondria in the absence of AMBRA1 (Supplementary Figure S2B).

These results indicate that AMBRA1\textsuperscript{ActA} confers protection from cell death-induced by rotenone thanks to its mitophagic activity.

**AMBRA1\textsuperscript{ActA}-Induced Mitophagy Protects SH-SY5Y Cells From Oxidative Stress Generated by Both 6-OHDA and Rotenone**

Although the exact molecular etiology of PD is largely unclear, mitochondrial oxidative stress and accumulated dysfunctional mitochondria are critical factors in the onset of the disease. Thus, we hypothesized that AMBRA1\textsuperscript{ActA}-induced mitophagy was able to also protect neuroblastoma cells from neurotoxicity, this being probably due to an anti-oxidative effect. In fact, accumulation of ROS by mitochondria can be reduced by activation of mitochondrial clearance. To test this hypothesis, we transfected SH-SY5Y cells with a vector encoding PcDNA3 or Myc-AMBRA1\textsuperscript{ActA}, and treated them with 6-OHDA (100 \(\mu\text{M}\)) or rotenone (10 \(\mu\text{M}\)) for 18 h. Oxidative modification of proteins by oxygen-free radicals and other reactive species occurs in physiological and pathological processes. As a consequence of the modification, carbonyl groups are introduced into protein side chains by a site-specific mechanism. We thus decided to immunodetect these carbonyl groups, which are hallmarks of protein oxidation status upon 6-OHDA or rotenone treatment in cells overexpressing Myc-AMBRA1\textsuperscript{ActA} or PcDNA3 as a control. As shown in Figures 4A,B, Myc-AMBRA1\textsuperscript{ActA} expression is sufficient to reduce protein carbonylation, upon 6-OHDA or rotenone treatments. To strengthen these results, we analyzed the ROS status through the fluorogenic dye MitoSOX Red coupled to flow cytometry analysis. SH-SY5Y cells were transfected with a biscistronic construct (Tween-GFP-AMBRA1\textsuperscript{ActA}) encoding AMBRA1\textsuperscript{ActA} and a cytosolic GFP, or the GFP alone, in order to select cells positive to transfection. Cells were then treated with 6-OHDA and rotenone, as indicated above. As shown in Figures 4C,D, 6-OHDA and rotenone strongly stimulate ROS production, an effect attenuated upon AMBRA1\textsuperscript{ActA} overexpression.

These results indicate that AMBRA1\textsuperscript{ActA} expression reduces oxidative stress induction in SH-SY5Y cells, following induction of neurotoxicity. Next, since the formation of mitochondrial ROS (mitROS) is dependent on \(\Delta\psi_m\) (Korshunov et al., 1997), we checked for mitochondrial membrane status using Tetramethylrhodamine, methyl ester (TMRM) in AMBRA1\textsuperscript{ActA} positive cells, following 6-OHDA or rotenone treatments. As shown in Figure 4E, 6-OHDA or rotenone reduce the TMRM signal in control cells, thus confirming an alteration in the mitochondrial membrane potential. By contrast, as previously observed, we found that AMBRA1\textsuperscript{ActA} surrounds depolarized mitochondria and the 6-OHDA or rotenone treatment does not affect mitochondrial membrane potential in AMBRA1\textsuperscript{ActA}-transfected cells. Altogether, these data suggest that AMBRA1\textsuperscript{ActA} expression is sufficient to improve mitochondrial membrane status upon neurotoxin treatments.

**DISCUSSION**

Our previous study performed on mouse embryonic fibroblasts from PINK1\textsuperscript{−/−} mice or by using fibroblasts derived from PARKIN and PINK1-mutated PD patients provided evidence that AMBRA1 can mediate mitophagy in the absence of PARKIN or PINK1 activities (Strappazzon et al., 2015). Here, primed by these findings, we decided to investigate the putative therapeutic potential of AMBRA1 to rescue mitochondrial dysfunction in two in vitro models of ROS-induced dopaminergic cell death.

Oxidative stress, which can be due to several genetic and environmental factors, is believed to be one of the major mediators of PD pathogenesis. The role of oxidative stress produced by dopamine for neuronal cell survival has been demonstrated in several works (Offen et al., 1996; Gilgun-Sherki et al., 2001). Interestingly, dysfunctional mitochondria are thought to be the predominant source of ROS (Jiang et al., 2016).

In this study, we first decided to mimic PD in vitro, by using 6-OHDA, the pro-oxidant derivate of dopamine widely used in ROS-induced dopaminergic cell death model systems. Indeed, 6-OHDA has been shown to increase protein oxidation (accumulation of carbonylated protein), and to increase both caspases-3/7 activity and nuclear fragmentation (Elkon et al., 2002; Hanrott et al., 2006). Interestingly, neurotoxicity of 6-OHDA is significantly attenuated by pre-incubation with catalase, this suggesting that hydrogen peroxide, at least in part, is responsible for cell death in this model. Here we report that AMBRA1\textsuperscript{ActA} expression is sufficient to induce functional mitophagy in neural dopaminergic SH-SY5Y cells. In addition, we found that cell metabolism was improved in the presence of AMBRA1\textsuperscript{ActA} and was associated to apoptosis reduction (reduction of PARP cleavage and occurrence of pyknotic nuclei), following 6-OHDA treatment.

We also investigated the putative beneficial role of AMBRA1\textsuperscript{ActA}-mediated mitophagy in a second model of
AMBRA1-

mediated mitophagy reduces oxidative stress

Di Rita et al. AMBRA1-Mediated Mitophagy Reduces Oxidative Stress

FIGURE 4 | AMBRA1(Aca) reduces oxidative stress induced by 6-OHDA and rotenone treatments in SH-SYSY cells. (A) Protein carbonylation analysis of SH-SYSY cells transfected with vectors encoding PcdNA3 or Myc-AMBRA1(Aca) for 24 h and treated or not with 6-OHDA. The graph showing protein oxidation status (A.U.) results as the mean of three independent experiments (± S.D.). Statistical analysis was performed using One-way ANOVA. ***P < 0.0001; **P < 0.01; *P < 0.05. n = 3 independent experiments. (B) SH-SYSY cells were transfected as indicated in (A) and treated or not with rotenone. The graph shows protein oxidation status (A.U.) and results as the mean of three independent experiments (± S.D.). Statistical analysis was performed using One-way ANOVA. ***P < 0.001; **P < 0.01; *P < 0.05. n = 3 independent experiments. (C) SH-SYSY cells were transfected with constructs encoding Tween-GFP or Tween-GFP-AMBRA1(Aca) for 24 h and treated or not with 6-OHDA. Cells were subsequently stained with MitoSOX Red and analyzed by flow cytometry to measure the fluorescence intensity of the dye in GFP positive cells. Data are presented as Mean ± S.D of four independent experiments. Statistical test: One-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001. (D) SH-SYSY cells were transfected with constructs encoding Tween-GFP or Tween-GFP-AMBRA1(Aca) for 24 h and treated or not with rotenone. Cells were subsequently stained with MitoSOX Red and analyzed by flow cytometry to measure the fluorescence intensity of the dye in GFP positive cells. Data are presented as Mean ± S.D of four independent experiments. Statistical test: One-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; n.s.: not statistically significant. (E) SH-SYSY cells were transfected with a plasmid encoding Tween-GFP or Tween-GFP-AMBRA1(Aca) and then treated or not with rotenone or 6-OHDA or FCCP. Cells were subsequently stained with 5 nM TMRM and analyzed by flow cytometry to measure the fluorescence intensity of the dye in GFP positive cells. Data are presented as Mean ± S.D of three independent experiments. Statistical test: One-way ANOVA. **P < 0.01; ***P < 0.0001; n.s.: not statistically significant.

PD by using rotenone. Rotenone is, indeed, a commonly used pesticide, which has been associated with increased risk for PD (Chin-Chan et al., 2015). It is an inhibitor of mitochondrial complex I (Degli Esposti et al., 1993) and it is believed to be a strong ROS producer (McLennan and Degli Esposti, 2000). Systemic chronic exposure of rats to rotenone causes a selective
PD progression. We are now proposing AMBRA1 as a novel potent brain-penetrating antioxidants might act to slow down cell viability following 6-OHDA treatment, this indicating that antioxidant-reduced glutathione has been shown to improve by attenuating oxidative stress. Interestingly, the endogenous the survival of SH-SY5Y cells treated with rotenone, we were able to delay apoptosis of human neuroblastoma cells.

These data are of the highest interest, since we were able to show that AMBRA1-mediated mitophagy is cell protective in two independent models of ROS-induced dopaminergic cell death (by 6-OHDA or rotenone). We thus here propose a model by which AMBRA1 expression at the mitochondria is sufficient to reduce ROS accumulation generated by neurotoxin (6-OHDA or rotenone) exposure. This protective effect is due to AMBRA1-mediated mitophagy that favors elimination of dysfunctional mitochondria, thus preventing cells from undergoing death. Indeed, our results strongly suggest that AMBRA1 is a promising target for limiting ROS production and toxin-induced cell death. Of note, it has been recently demonstrated that the mitochondria autophagy receptor Nip3-like protein X, named NIX [also known as BCL2/adenovirus E1B 19 kDa interacting protein 3-like (BNIP3L)] can restore mitophagy and mitochondrial function in fibroblasts from PINK1-PARKIN-mutated PD Patients (Koentjoro et al., 2017). Since NIX, similar to AMBRA1, induces alternative mitophagy (PINK1- and PARKIN-free), it would be of the highest interest to test in this context whether NIX-mediated mitophagy can rescue cell death following 6-OHDA or rotenone treatments in human neuroblastoma cell lines. Interestingly, AMBRA1 presents several common features with NIX such as: (1) a mitochondrial localization (Strappazzon et al., 2011); an LC3-Interacting Region (Strappazzon et al., 2015); a BH3-Like domain (Strappazzon et al., 2016). We could thus hypothesize that AMBRA1 and NIX work in synergy or by separate pathways that may compensate each other. Under physiological conditions, it has been demonstrated that NIX mediates mitophagy in erythrocytes. In particular, Nix knockout mice exhibit a reduced number of mature erythrocytes and show defects in mitochondrial clearance (Sandoval et al., 2008). To better understand the function of AMBRA1-alternative mitophagy in vivo, it will also be of great interest, and in line with the role of NIX, to examine Ambra1 deficient mice in the hematopoietic system.

Further studies are needed to better understand the mechanisms by which AMBRA1-mediated mitophagy is initiated and to determine whether AMBRA1-mediated mitophagy could be pharmacologically induced in vivo in order to ameliorate the mitochondrial defects observed in human dopaminergic neurons in models of PD.

Finally, we reported here that AMBRA1 is able to favor the survival of SH-SY5Y cells following neurototoxic stimuli by attenuating oxidative stress. Interestingly, the endogenous antioxidant-reduced glutathione has been shown to improve cell viability following 6-OHDA treatment, this indicating that potent brain-penetrating antioxidants might act to slow down PD progression. We are now proposing AMBRA1 as a novel target to reduce oxidative stress; indeed, this molecule could be modulated in the future as a pharmacological target in brains of PD patients or other patients with pathologies associated to oxidative stress.

In sum, our data strongly suggest that alternative mitophagy mediated by AMBRA1 can exert protective effects against PD-related neuronal injury, through inhibiting oxidative stress and mitochondrial dysfunction.

AUTHOR CONTRIBUTIONS

AD performed the majority of the experiments planned together with FS and FC. PD performed cloning. PD, LS and SC performed FACS analysis. AD, FS and FC wrote the manuscript.

FUNDING

This work was supported by grants GR2011-02351433 to FS; AIRC (IG2016–18906), Fondazione Roma, KBUV from the Danish Cancer Society (R146-A9364), the Novo Nordisk Foundation (7559, 22544) and the European Union (Horizon 2020 MEL-PLEX, grant agreement 195 642295) to FC. Further, FC lab in Copenhagen is part of the Center of Excellence in Autophagy, Recycling and Disease (CARD), funded by the Danish National Research Foundation.

ACKNOWLEDGMENTS

We wish to thank Prof. M. Campanella (Royal Veterinary College, University of London, UK) and Dr. P. P. Leoncini ("Bambino Gesù" Children’s Hospital, Rome, Italy) for the gift of Short Hairpin PARKIN and Twee-GFP plasmids, respectively. We acknowledge Prof. D. Barilà (University of Rome, Tor Vergata, Italy) who kindly provided SH-SY5Y cells.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fncel.2018.00092/full#supplementary-material

FIGURE S1 | The recombinant protein AMBRA1Ala induces mitophagy in SH-SY5Y. SH-SY5Y cells transfected with pcDNA3 (empty vector) and with plasmids encoding the recombinant proteins VenusAla, Myc-AMBRA1Ala, or Myc-AMBRA1ΔC0ΔLPPA and the wild-type protein Myc-AMBRA1 were fixed and stained for anti-HSP60 (red) and DAPI (blue). Scale bar, 6 µm. P<0.0001; *P<0.05.

FIGURE S2 | Endogenous AMBRA1 downregulation produces a delay in mitochondrial clearance in 6-OHDA- or rotenone-treated cells. (A) SH-SY5Y cells were transfected with siRNA-Ctr or a siRNA against AMBRA1 and treated with 6-OHDA for 18 h, Total lysates were subjected to western blotting analysis for the indicated antibodies. (B) Total lysate of SH-SY5Y cells downregulated for AMBRA1, through siRNA-AMBRA1 transfection were treated with rotenone for 18 h and then analyzed by western blotting analysis looking to mitochondrial marker MnSOD level.
REFERENCES

Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., and Greenamyre, J. T. (2000). Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat. Neurosci. 3, 1301–1306. doi: 10.1038/11834

Bolte, S., and Cordelières, F. P. (2006). A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc. 224, 213–232. doi: 10.1111/j.1365-2818.2006.01706.x

Chin-Chan, M., Navarro-Yepes, J., and Quintanilla-Vega, B. (2015). Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front. Cell. Neurosci. 9:124. doi: 10.3389/fncel.2015.00124

Degli Esposti, M., Ghelli, A., Crimi, M., Estornell, E., Fato, R., and Lenaz, G. (1993). Complex I and complex III of mitochondria have common inhibitors acting as ubiquinone antagonists. Biochem. Biophys. Res. Commun. 190, 1090–1096. doi: 10.1006/bbrc.1993.1161

Elkon, H., Don, J., Melamed, E., Ziv, I., Shirvan, A., and Offen, D. (2002). Mutant and wild-type α-synuclein interact with mitochondrial cytochrome C oxidase. J. Mol. Neurosci. 18, 229–238. doi: 10.1385/jnms:18:3.229

Gigun-Sherki, Y., Melamed, E., and Offen, D. (2001). Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropsychopharmacology 40, 959–975. doi: 10.1016/s0220-3457(01)00019-3

Glinka, Y., Gassen, M., and Youdim, M. B. (1997). Mechanism of 6-hydroxydopamine neurotoxicity. J. Neural Transm. Suppl. 50, 55–66. doi: 10.1007/978-3-7091-6842-4_7

Hanrott, K., Gudmunsen, L., O’Neill, M. J., and Wonnacott, S. (2006). 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J. Biol. Chem. 281, 5373–5382. doi: 10.1074/jbc.M511560200

Hart, P. D., and Young, M. R. (1991). Ammonium chloride, an inhibitor of phagosome-lysosome fusion, and opens a novel pathway: studies of a pathogenic mycobacterium and a nonpathogenic yeast. J. Exp. Med. 174, 881–889. doi: 10.1084/jem.174.4.881

Jiang, L., Shestov, A. A., Swain, P., Yang, C., Parker, S. J., Wang, Q. A., et al. (2016). AMBRA1-Mediated Mitophagy Reduces Oxidative Stress. J. Biol. Chem. 281, 8516–8525. doi: 10.1074/jbc.m210432200

Lin, M. T., and Beal, M. F. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787–795. doi: 10.1038/nature05292

McLennan, H. R., and Degli Esposti, M. (2000). The contribution of mitochondrial respiratory complexes to the production of reactive oxygen species. J. Bioenerg. Biomembr. 32, 153–162. doi: 10.1023/A:1005507913372

Nagai, T., Ibata, K., Park, E. S., Kubota, M., Mikoshiba, K., and Miyawaki, A. (2002). A variant of yellow fluorescent protein with fast and efficient maturation for cell biological applications. Nat. Biotechnol. 20, 87–90. doi: 10.1038/nbt0102-87

Ofen, D., Ziv, I., Sternin, H., Melamed, E., and Hochman, A. (1996). Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson’s disease. Exp. Neurol. 141, 32–39. doi: 10.1006/exnr.1996.0136

Pankiv, S., Clausen, T. H., Lamark, T., Brech, A., Bruun, J. A., Outzen, H., et al. (2007). p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J. Biol. Chem. 282, 24131–24145. doi: 10.1074/jbc.M702842200

Sanders, L. H., McCoy, J. H., Xu, M., Mastroberardino, P. G., Dickinson, B. C., Chang, C. J., et al. (2014). Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson’s disease. Neurobiol. Dis. 70, 214–223. doi: 10.1016/j.nbd.2014.06.014

Sandoval, H., Thiagarajan, P., Dasgupta, S. K., Schumacher, A., Prchal, J. T., Chen, M., et al. (2008). Essential role for Nix in autophagic maturation of erythroid cells. Nature 454, 232–235. doi: 10.1038/nature07006

Sherer, T. B., Betarbet, R., Kim, J. H., and Greenamyre, J. T. (2003). Selective microglial activation in the rat rotenone model of Parkinson’s disease. Neurosci. Lett. 341, 87–90. doi: 10.1016/j.snb.2003.09.072-1

Siddiqui, M. A., Ahmad, I., Farshori, N. N., Saquib, Q., Jahan, S., Kashyap, M. P., et al. (2013). Rotenone-induced oxidative stress and apoptosis in human liver HepG2 cells. Mol. Cell. Biochem. 384, 59–69. doi: 10.1007/s11010-013-1781-9

Strappazzon, F., Di Rita, A., Gianfanelli, V., D’Orazio, M., Nazio, F., Fimia, G. M., et al. (2016). Prosurvival AMBRA1 turns into a proapoptotic BH3-like protein during mitochondrial apoptosis. Autophagy 12, 963–975. doi: 10.1080/15548627.2016.1164559

Strappazzon, F., Nazio, F., Corrado, M., Gianfanelli, V., Romagnoli, A., Fimia, G. M., et al. (2015). AMBRA1 is able to induce mitophagy via LC3 binding, regardless of PARKIN and p62/SQSTM1. Cell Death Differ. 22, 419–432. doi: 10.1038/cdd.2014.139

Strappazzon, F., Vetri-Rudan, M., Campello, S., Nazio, F., Florenzano, F., Fimia, G. M., et al. (2011). Mitochondrial BCL-2 inhibits AMBRA1-induced autophagy. EMBO J. 30, 1195–1208. doi: 10.1038/emboj.2011.49

Van Humbeeck, C., Cornelissen, T., Hofkens, H., Mandemakers, W., Gevaert, K., Strappazzon, F., Nazio, F., Corrado, M., Cianfanelli, V., Romagnoli, A., et al. (2011). Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson’s disease. Autophagy 7, 24131–24145. doi: 10.1080/15548627.2011.105292

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Di Rita, D’Acunzo, Simula, Campello, Strappazzon and Cecconi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.